Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agenix has submitted a method of manufacturing patent application under the Patent Cooperation Treaty (PCT) for its hepatitis B drug AGX-1009.
Subscribe to our email newsletter
The patent application includes the manufacturing process of a compound that uses the
same active ingredient, Tenofovir, used in a drug marketed by Gilead Sciences under the trade name Viread.
Both drugs work by blocking an enzyme the hepatitis virus needs to replicate.
The company expects to start a Phase I human safety trial to evaluate AGX-1009 in 2012.
Agenix chairman and CEO Nicholas Weston said this important patent application confers further certainty in China and increases the commercial value of this treatment for hepatitis B in geographies outside of China.
"We continue to expand our patent portfolio which is fundamental to our future commercial licensing,
clinical development and strategic business partnerships with global pharmaceutical companies," Weston said.